Citadel Advisors’s Harpoon Therapeutics, Inc. Common Stock HARP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-685,000
| Closed | -$7.79M | – | 15870 |
|
|
2023
Q4 | $7.79M | Buy |
685,000
+636,244
| +1,305% | +$5M | ﹤0.01% | 3170 |
|
|
2023
Q3 | $196K | Buy |
48,756
+48,119
| +7,554% | +$357K | ﹤0.01% | 9949 |
|
|
2023
Q2 | $4.53K | Buy |
+637
| New | +$4.41K | ﹤0.01% | 13590 |
|
|
2023
Q1 | – | Sell |
-1,446
| Closed | -$12.2K | – | 15897 |
|
|
2022
Q4 | $10.5K | Buy |
+1,446
| New | +$12.2K | ﹤0.01% | 13616 |
|
|
2022
Q3 | – | Sell |
-12,940
| Closed | -$242K | – | 13982 |
|
|
2022
Q2 | $247K | Buy |
+12,940
| New | +$335K | ﹤0.01% | 10247 |
|
|
2022
Q1 | – | Sell |
-1,760
| Closed | -$91.2K | – | 14964 |
|
|
2021
Q4 | $133K | Sell |
1,760
-4,533
| -72% | -$309K | ﹤0.01% | 12421 |
|
|
2021
Q3 | $497K | Buy |
6,293
+3,636
| +137% | +$366K | ﹤0.01% | 9884 |
|
|
2021
Q2 | $368K | Sell |
2,657
-28
| -1% | -$5.34K | ﹤0.01% | 10776 |
|
|
2021
Q1 | $562K | Buy |
2,685
+481
| +22% | +$96.4K | ﹤0.01% | 9426 |
|
|
2020
Q4 | $366K | Sell |
2,204
-2,814
| -56% | -$435K | ﹤0.01% | 8730 |
|
|
2020
Q3 | $853K | Buy |
5,018
+396
| +9% | +$57.1K | ﹤0.01% | 6322 |
|
|
2020
Q2 | $768K | Buy |
+4,622
| New | +$721K | ﹤0.01% | 6316 |
|
Citadel Advisors's HARP Position: Q1 2024 in Review
Citadel Advisors sold out of Harpoon Therapeutics, Inc. Common Stock (HARP) in Q1 2024, closing a stake of 685,000 shares — an estimated $7.79M sold.
Citadel Advisors first reported a position in HARP in Q2 2020 and held it in 12 quarters. The position peaked at $7.79M in Q4 2023. 0 funds tracked by Wall St. Rank hold HARP as of Q1 2024.
- Citadel Advisors reported no remaining Harpoon Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
- Citadel Advisors sold 685,000 Harpoon Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $7.79M.
- Citadel Advisors first reported a position in Harpoon Therapeutics, Inc. Common Stock in Q2 2020 and held it in 12 quarters.
- Citadel Advisors's Harpoon Therapeutics, Inc. Common Stock position peaked at $7.79M in Q4 2023.
- 0 funds tracked by Wall St. Rank held Harpoon Therapeutics, Inc. Common Stock as of Q1 2024.
Based on Citadel Advisors's 13F filing for Q1 2024, filed 15 May 2024.